Repositioning Immunotherapy in VetArans With Lung Cancer
NCT06275360
This study is recruiting at 7 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- VA Office of Research and Development
- Last updated on ClinicalTrials.gov
- March 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT · West Haven, CT
District of Columbia · 1
- VA Central Office, Washington, DC · Washington D.C., DC
Indiana · 1
- Richard L. Roudebush VA Medical Center, Indianapolis, IN · Indianapolis, IN
Michigan · 1
- VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, MI
Nebraska · 1
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE · Omaha, NE
Texas · 1
- Michael E. DeBakey VA Medical Center, Houston, TX · Houston, TX
Virginia · 1
- Richmond VA Medical Center, Richmond, VA · Richmond, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.